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Background: Treatment guidelines for Clostridioides difficile infection (CDI) were updated by 
the Infectious Disease Society of America (IDSA) & the Society for Healthcare Epidemiology of 
America (SHEA) in 2017 making various modifications, most notably for disease severity & 
treatment recommendations. Our objectives were to assess Connecticut medical providers’ 
concordance (2017-2019) to the 2017 SHEA/IDSA clinical treatment guidelines. The effect of 
guideline concordance on the risk of CDI recurrence was also assessed. 
Methods:  Using data from the Connecticut Emerging Infections Program’s CDI surveillance in 
New Haven County, severity & concordance were defined for CDI cases. For severity, white 
blood cell count >15,000 & presence of megacolon and/or ileus were used. Concordant treatment 
was defined as receiving the recommended first-line antibiotic (vancomycin for adult patients, 
vancomycin or metronidazole for pediatric patients) for exactly 10 days.  In univariate & 
multivariate analyses, significance was determined by a p-value of <0.05.  
Results: Of the 1,216 New Haven County incident cases eligible for the study (50.7%) from 
2017 - 2019, an overall concordance of 23.0% was identified, increasing from 10.0% in 2017 to 
36.9% in 2019. Concordance with initial choice of first line treatment increased from 40.2% in 
2017 to 80.8% in 2019. Overall concordance was highest for cases with fulminant disease 
(62.2%). The recurrence rate was 11.2% & was highest for patients with non-severe disease & 
older age but was not significantly associated with treatment concordance.   
Conclusion: From 2017 through 2019, CDI treatment in New Haven County increasingly was 
concordant with the updated 2017 IDSA/SHEA guidelines, but as of 2019, the overall level was 
still low except for those with severe disease. Although concordance with treatment did not 
affect recurrence risk, close attention should be paid by medical providers to patients who are 
classified as non-severe and/or elderly as they are at an increased risk for recurrence. 
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CDI is a well-known cause of healthcare-associated (HA) infectious diarrhea, surpassing 
Staphylococcus aureus as the most common cause for hospital-acquired infections.1 Surveillance 
of CDI in the last decade has also revealed the rise of community-acquired cases (CA), shifting 
public health interest towards understanding their causes.2 The national burden of CDI was 
estimated in 2011 to be 293,300 HA-CDI cases, 159,700 CA-CDI cases and 29,300 deaths per 
year.3 To reduce the morbidity and mortality of CDI cases, the Society for Healthcare 
Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) 
routinely revise their national guidelines for CDI treatment based on emerging CDI 
treatment/diagnostic data.  
With a growing evidence base for the effectiveness of vancomycin treatment,4 5 the 2017 
IDSA/SHEA guidelines were created to update the 2010 guidelines in no longer recommending 
metronidazole as a first-line treatment option, instead encouraging vancomycin or fidaxomicin as 
a first-line alternative.6 Secondly, the definition of disease severity changed: ‘mild/moderate’ 
                                                        
1 Magill, Shelley S., Jonathan R. Edwards, Wendy Bamberg, Zintars G. Beldavs, Ghinwa Dumyati, Marion A. Kainer, 
Ruth Lynfield et al. "Multistate point-prevalence survey of health care–associated infections." New England Journal 
of Medicine 370, no. 13 (2014): 1198-1208. 
2 Khanna, Sahil, Darrell S. Pardi, Scott L. Aronson, Patricia P. Kammer, Robert Orenstein, Jennifer L. St Sauver, W. 
Scott Harmsen, and Alan R. Zinsmeister. "The epidemiology of community-acquired Clostridium difficile infection: a 
population-based study." The American journal of gastroenterology 107, no. 1 (2012): 89. 
3 Lessa, Fernanda C., Yi Mu, Wendy M. Bamberg, Zintars G. Beldavs, Ghinwa K. Dumyati, John R. Dunn, Monica M. 
Farley et al. "Burden of Clostridium difficile infection in the United States." New England Journal of Medicine 372, 
no. 9 (2015): 825-834. 
4 Stevens, Vanessa W., Richard E. Nelson, Elyse M. Schwab-Daugherty, Karim Khader, Makoto M. Jones, Kevin A. 
Brown, Tom Greene et al. "Comparative effectiveness of vancomycin and metronidazole for the prevention of 
recurrence and death in patients with Clostridium difficile infection." JAMA internal medicine 177, no. 4 (2017): 
546-553. 
5 Johnson, Stuart, Thomas J. Louie, Dale N. Gerding, Oliver A. Cornely, Scott Chasan-Taber, David Fitts, Steven P. 
Gelone, Colin Broom, David M. Davidson, and Polymer Alternative for CDI Treatment (PACT) investigators. 
"Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, 
randomized, controlled trials." Clinical Infectious Diseases 59, no. 3 (2014): 345-354. 
6 Wilcox, Mark H., and Christopher M. Rooney. "Comparison of the 2010 and 2017 Infectious Diseases Society of 
America guidelines on the diagnosis and treatment of Clostridium difficile infection." Current opinion in 
gastroenterology 35, no. 1 (2019): 20-24. 
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became ‘non-severe’, ‘severe’ remained the same, and ‘severe (complicated)’ became 
‘fulminant’. For non-severe as well as severe cases, vancomycin 125mg given orally four times 
daily for 10 days or fidaxomicin 200mg given orally twice daily for 10 days is recommended. 
Vancomycin 500mg given orally four times daily, or by nasogastric tube in rare instances, is 
recommended for fulminant cases.7 
  While the 2017 guidelines aim to incorporate the newer evidence base, there is concern 
about medical provider concordance with these revisions, which is likely affected by timely 
dissemination of these changes.8 9 Assessing concordance of CT medical providers with these 
guidelines will identify differences in treatment patterns as well as clinical outcomes, and help 
identify consequences, such as recurrent CDI, in cases where discordance is identified.  
The CT Emerging Infections Program (CT-EIP) has been conducting enhanced 
surveillance for CDI since 2011 in New Haven County. A previous study using data from these 
surveillance efforts examined concordance with the previous 2010 IDSA/SHEA treatment 
guidelines.10 This previous study looked at the unadjusted association between concordant care 
and CDI recurrence and did not find any significant association. The objectives of this study 
were to assess Connecticut medical providers’ concordance (2017-2019) to the 2017 
SHEA/IDSA clinical treatment guidelines for CDI by assessing concordance of their prescribed 
CDI treatment regimen with the 2017 guidelines. We focused specifically on the first-line 
treatment prescribed and its duration to define concordance. Once concordance was assessed, we 
                                                        
7 Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by IDSA & SHEA 
8 Bariola, J. Ryan, and Tina Khadem. "1987. Impact of Updated IDSA Clostridium difficile Guidelines on the use of 
Fidaxomicin in a Large Health System." In Open Forum Infectious Diseases, vol. 6, no. Supplement_2, pp. S666-
S666. US: Oxford University Press, 2019. 
9 Clancy, Cornelius J., and Minh-Hong Nguyen. "779. Impact of updated IDSA practice guidelines on the treatment 
of Clostridium difficile infections in the United States." In Open Forum Infectious Diseases, vol. 6. 2019. 
10 Martinez, (2018). 
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highlighted changes in concordance from this study with 2013-2016 Connecticut data collected 
by Martinez et al. (2018) which examined concordance with the 2010 guidelines.11 Lastly, the 
adjusted association of concordance on the risk of CDI recurrence was assessed, identifying the 




 As a CDC-funded program with a protocol that underwent ethical review by the CDC, 
the CDI surveillance program of the Emerging Infection Programs covers 35 counties in 10 
states, capturing more than 12 million people in 2017.12 The CT-EIP CDI surveillance system 
encompasses New Haven County, Connecticut. Laboratories serving New Haven County report 
all positive C. difficile tests to CT-EIP staff. A CDI case was defined as a C. difficile-positive 
stool test (toxin or molecular assay) from a person ≥1 year old who had no positive tests in the 
prior 8 weeks.13 Cases were designated into epidemiologic classifications: healthcare facility-
onset (HCFO), community-acquired (CA), or community onset-healthcare facility-associated 
(CO-HCFA). A case was classified as HCFO if the CDI was healthcare facility-onset CDI 
(positive stool collected more than three days after admission) from either a hospital or long-term 
care facility.14 A case was classified as community-onset (CO) if the positive stool was collected 
in an outpatient setting or within the three days of hospital admission. Of cases that were 
classified as CO, those that did not have documentation of admission to a healthcare facility in 
                                                        
11 Martinez, (2018). 
12 Guh, (2020). 
13 Guh, (2020). 
14 Guh, (2020). 
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the preceding 12 weeks of their stool were designated as CA and all other CO cases were 
considered CO-HCFA.15 
For this study, each CDI case was classified by clinical disease severity broken down into 
3 categories (non-severe, severe, and fulminant). Following the 2017 SHEA/IDSA clinical 
definitions, non-severe CDI cases were defined as having a white blood cell count of ≤15,000 
/µl; severe cases were defined as having a white blood cell count of >15,000 /µl; and fulminant 
cases were defined as having the presence of a toxic megacolon and/or ileus, regardless of white 
blood cell count.16  
For 2017 SHEA/IDSA guideline concordance, i.e., ‘guideline concordant care’, treatment 
was assessed by two factors: the duration of treatment and the concordant antibiotic prescribed. 
Duration of treatment was defined by the specific duration that the healthcare provider ordered. 
Three possible scenarios explain how these durations were captured by EIP staff: 1. If a patient 
was hospitalized for the entire prescribed treatment period, the electronic patient chart was 
consulted. 2. If a patient was hospitalized for a portion of the prescribed treatment period, the 
electronic patient chart and the discharge summary, which represents medication administered in 
the hospital and medication prescribed after discharge, were consulted. 3. If the patient was not 
hospitalized and sought care from their outpatient provider or went to an emergency department 
or urgent care, the electronic order containing the prescribed treatment period, from their 
provider in the given care setting, was consulted.  
First-line treatment was classified as either the sole antibiotic prescribed for the first-line 
treatment or the treatment given for the longest duration, if two treatments were noted in the 
                                                        
15 Guh, (2020). 
16 IDSA/SHEA, (2017) 
 
 10 
chart review. Of cases that had two treatments of equal duration, first-line treatment was 
designated as a combination. Treatment dosage, route of administration and frequency of dosing 
(i.e., twice daily, every six or eight hours) was not assessed due to these clinical variables being 
dropped in 2018 and 2019 CT-EIP data collection. For pediatric patients, guideline concordance 
care was denoted as taking vancomycin or metronidazole for a 10-day duration regardless of 
severity. For adult patients, guideline concordant care for non-severe and severe CDI cases was 
defined as taking vancomycin or fidaxomicin for a 10-day duration, and vancomycin for 
fulminant cases. Assessment of concordance in fulminant cases did not factor in treatment 
duration as the 2017 SHEA/IDSA guidelines do not specify duration. Therefore, any fulminant 
cases treated with vancomycin were deemed guideline concordant. Since concordant duration is 
noted as strictly 10 days by the 2017 IDSA/SHEA guidelines, treatment duration greater than or 
less than 10 days was deemed guideline discordant.  
For analysis, cases with missing laboratory and treatment data were removed. Unadjusted 
associations with concordant care and study variables, as well as recurrent CDI and study 
variables were calculated for the adult study sample (≥18 years old) due to differences in 
treatment recommendations for pediatric and adult patients. Finally, a multivariable logistic 
regression of this sample was created using backwards elimination with the outcome of recurrent 
CDI, the main predictor (guideline discordant care), and potential confounders.  
 
Results: 
Overall Study  
 Of the 2,399 New Haven County incident cases from 2017 - 2019, 1,232 (51.4%) had 
complete laboratory and clinical characteristics to identify case severity and concordance. Cases 
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with complete data compared to those who were excluded were more likely to be male, older, 
non-Hispanic White or Black , HCFA or CO-HCFO, have underlying conditions and antecedent 
antibiotic use. (Table 1). Of the 1,232 cases that had complete laboratory and clinical 
characteristics, 16 who were taking the concordant form of treatment died before reaching the 
concordant duration of treatment. These 16 cases were deemed ineligible for the study; the 1,216 
cases who had complete data were used for analysis.  
Of these 1,216 cases, 280 (23.0%) had guideline concordant care. Of all 2017 cases, 39 
cases (10.0%) were guideline concordant. In 2019, 136 cases (36.9%) were guideline 
concordant, an average increase in concordance of 13.5% per year over the three-year period. 
Guideline concordant antibiotics increased from 157 cases (40.2%) in 2017 to 298 cases (80.8%) 
in 2019, an average increase of 20.3% in the concordant initially prescribed antibiotic per year 
over the three-year period. Of cases prescribed the concordant antibiotic, the concordant duration 
of treatment increased from 39 cases (24.8%) in 2017 to 136 cases (45.6%) in 2019, an average 
increase of 10.4% in the concordant duration of treatment per year over the three-year period 
(Figure 1). 
Table 2 shows the description of the study by year, including data from 2013-2016. The 
2017-2019 total guideline concordance of 23.0% was more than twice as high as the 2013-2016 
total guideline concordance of 8.7% which followed the 2010 SHEA/IDSA guidelines.17 First-
line treatment with vancomycin increased with each subsequent year from 2017-2019, with 292 
cases (79.1%) receiving vancomycin in 2019. First-line treatment with metronidazole decreased 
with each subsequent year from 2017-2019, with 72 cases (19.5%) receiving metronidazole in 
2019. Further, Table 3 delineates the specific frequencies of duration (by days) for the study, 
                                                        
17 Martinez, (2018).  
 12 
which included the 16 cases who died before they could get 10 days of treatment. A total of 
32.8% of patients getting vancomycin received it for 10 days. For those receiving metronidazole, 
20.5% received it for 10 days. (Table 3). 
 
Pediatric Cases 
 Of the 1,216 cases, there were 21 pediatric cases (<18 years old). Of these, 17 (81.0%) 
were denoted as non-severe, one case (4.8%) as severe, and three cases (14.3%) as fulminant. 
Twelve (12) cases (57.1%) received concordant treatment, a significantly higher proportion than 
for adults (268, 22.4%) (P<0.001). Overall, 14 of the cases (66.7%) were epidemiologically 
classified as CA, six cases (28.6%) were CO-HCFA, and one case (4.8%) was HCFO. One case 
(4.8%) had recurrent CDI.  
 
Adult Cases 
Table 4 shows the distribution of adult cases by severity of CDI and selected 
characteristics. Of the 1,195 adult cases (≥18 years old) with complete data, 790 (66.1%) were 
classified as non-severe, 368 (30.8%) as severe, and 37 cases (3.1%) as fulminant. Statistically 
significant associations noted include: guideline concordant care and severity, with fulminant 
cases having the highest proportion of guideline concordant care (62.2%); age, both as a 
continuous and categorical variable, and severity, with fulminant cases as having the highest 
average age (72.57 ± 15.33) and highest percentage of those aged 65-74 years (35.1%), 75-84 
(21.6%), and ≥85 (24.3%); epidemiologic classification and severity, with non-severe having the 
highest percentage of CA (53.8%), severe as having the highest percentage of CO-HCFA 
(39.4%), and fulminant having the highest percentage of HCFO (21.6%); and any previous 
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antibiotic use and severity, with non-severe having the highest percentage of previous antibiotic 
use (31.7%) (Table 4). 
Table 5 shows the associations in adults between guideline care and study variables. 
Without adjusting for confounding, the odds of having concordant care progressively increased 
from 2017 to 2019. In 2018, it was 3.00 times higher than 2017 (95% CI; 1.98, 4.54), and in 
2019 it was 5.95 times higher (95% CI; 3.94, 8.99). The odds of having concordant care in 
fulminant cases was 5.57 times the odds of having concordant care for non-severe cases (95% 
CI; 2.81, 11.04); and in severe cases was 0.73 times the odds of having concordant care in non-
severe cases (95% CI; 0.53, 1.00) (Table 5). 
Table 6 shows the unadjusted association of having recurrent disease with study 
demographic and treatment variables in adults from 2017-2019. First noted in Table 2, there 
were 240 recurrent CDI cases in 2013-2016 (15.9% of 2013-2016 cases); and a reduced 
frequency of 136 recurrent CDI cases in 2017-2019 (11.2% of 2017-2019 cases).18 For these 136 
recurrent cases, the risk of having recurrent CDI was lower after receiving guideline non-
concordant care (the main predictor) than the risk after receiving guideline concordant care 
(OR=0.81), although not statistically significant (Table 6). The risk for severe cases was lower 
than for non-severe cases (OR=0.65, 95% CI; 0.43, 0.99), and was even lower for fulminant 
cases (OR= 0.39, 95% CI; 0.09, 1.65). Risk increased with each increasing age group compared 
to  the 18-44 age group, with the highest risk of having recurrent CDI for those  ≥85 years old 
(OR=2.45, 95% CI; 1.11-5.38). Due to this increasing directionality in the age group categorical 
variable, age was modeled as continuous in the multivariable logistic regression model.   
                                                        
18 Martinez, (2018). 
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Table 7 shows the results of multiple regression modeling for predictors of recurrent CDI. 
Adjusting for potential confounding, the risk of having recurrent CDI for discordant care 
remained lower than that for concordant care (OR=0.80), but this finding was not statistically 
significant. The risk of having recurrent CDI increased by 1.02 for each year of age (95% CI; 
1.01, 1.03). As in the unadjusted analysis, the risk of having recurrent CDI decreased with 
increasing disease severity: for severe cases it was approximately two-thirds that for non-severe 
cases (OR=0.63, 95% CI; 0.41, 0.95); and for fulminant cases was a third that of non-severe 
cases, a difference which in the multiple regression model was not statistically significant. 
Table 8 offers supplementary considerations to the role of treatment duration in reducing 
risk of CDI recurrence. The duration variable was modeled into further permutations and 
unadjusted ORs were created with the outcome of CDI recurrence. While these ORs changed 
based on the new permutations of duration, no significant findings could be drawn for either 
vancomycin or metronidazole first-line treatment.   
 
Discussion:  
To the best of our knowledge, this is the largest geographic-based prospective 
surveillance study evaluating prescribing practices for CDI. Other studies are either retrospective 
or single center, and more limited in scope. This study had a number of notable findings. 
Guideline concordant care in CDI cases from 2017-2019 increased with each subsequent year. 
Guideline concordant care increased as case severity increased. Treatment concordance, 
however, was not significantly associated with CDI recurrence. Controlling for all variables, a 
non-severe epidemiologic classification and increasing age increased the probability of 
recurrence. 
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Ten (10.0) percent of CDI cases in 2017 were guideline concordant while 36.9% of CDI 
cases in 2019 were guideline concordant. Overall 2017 SHEA/IDSA guideline treatment 
concordance for CDI cases in New Haven County was very low in 2017, but the increase in 
concordance with each subsequent year is encouraging. Our findings suggest that any change to 
treatment guidelines will not result in immediate uptake of the amendments and will require at 
least a multi-year period for change to be adopted by a majority of Connecticut providers. We 
did not systematically collect data on rationales behind Connecticut providers’ decisions to 
prescribe therapy inconsistent with treatment guidelines, but a small minority commented in the 
patient chart that the patient was allergic to first-line treatment or insurance providers did not 
cover vancomycin or fidaxomicin; this led to use of metronidazole as insurance coverage barriers 
are significant for vancomycin use which is not universally covered by insurance companies.19 
The proportion of cases with guideline concordant care increased with each subsequent 
degree of severity in cases, and the proportion of recurrent CDI decreased with each subsequent 
degree of severity in cases. This follows that cases that require more medical attention, severe 
and more so fulminant cases, receive more aggressive treatment regimens, reducing both 
discordance and potential risk for treatment failure. The highest proportion of CA cases were 
non-severe; the CO-HCFA or HA cases may be more likely to be sicker at baseline because they 
were recently hospitalized or in contact with healthcare than the CA cases. 
Guideline concordant care was not significantly associated with recurrent CDI, 
suggesting that the first-line antibiotic recommendation of vancomycin does not have a 
significant effect on CDI recurrence compared to other antibiotics, mainly, metronidazole. These 
                                                        
19 Bunnell, Kristen L., Larry H. Danziger, and Stuart Johnson. "Economic barriers in the treatment of Clostridium 
difficile infection with oral vancomycin." In Open forum infectious diseases, vol. 4, no. 2, p. ofx078. US: Oxford 
University Press, 2017. 
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findings are consistent with Martinez et al. (2018) as well as other evidence, including Stevens et 
al. (2017)  and Johnson et al. (2014) which are frequently referenced regarding first-line 
treatment options of CDI.  In a retrospective cohort study of >45,000 patients, Stevens et al. 
(2017) found that the recurrence rates of CDI among cases using vancomycin compared to cases 
using metronidazole for first-line treatment were similar. 20 The study concluded that the use of 
vancomycin is recommended over metronidazole for first-line treatment of CDI, but this was 
mostly due to a key finding that 30-day mortality was significantly lower in first-line treatment 
through vancomycin use.21 In a randomized controlled trial (RCT) of CDI first-line treatment 
with vancomycin, metronidazole and tolevamer, (Johnson et al. 2014) there were not any notable 
differences in CDI recurrence between the vancomycin and metronidazole groups. Interestingly, 
tolevamer did have a significantly lower CDI recurrence compared to the other groups.22 It was 
hypothesized that tolevamer does not disrupt gut microflora. Still, the use of vancomycin for 
first-line treatment had greater clinical success throughout the RCT; as tolevamer and 
metronidazole were deemed inferior to vancomycin use.23 As a significant reduction in CDI 
recurrence has not been demonstrated from vancomycin use in CDI patients, the 2017 
IDSA/SHEA guidelines recommendation of the use of vancomycin for a first recurrence of CDI 
is on a basis of a “weak recommendation, low quality of evidence.”24  Some evidence has 
emerged that fidaxomicin has a similar cure rate to vancomycin use with a significantly lower 
                                                        
20 Stevens, (2017). 
21 Stevens, (2017). 
22 Johnson, (2014). 
23 Johnson, (2014). 
24 IDSA/SHEA, (2017). 
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rate of early recurrence.25 26 Since fidaxomicin use was low in this study, no conclusions can be 
made to support this claim, but the role of fidaxomicin in reducing risk of CDI recurrence is 
worth further investigation. 
Although treatment concordance was not significantly associated with CDI recurrence, a 
non-severe epidemiologic classification and increasing age, controlling for all other variables, 
increased the probability of recurrence. Increasing susceptibility to disease as age increases may 
generally explain the increased risk of recurrent CDI in older age groups. Non-severity as a risk 
factor for recurrence is unknown. This is a topic for confirmation in other surveillance sites and, 
if confirmed, further investigation. Still, medical providers should pay close attention to patients 
who are classified as non-severe and/or elderly due to the increased risk for recurrence in these 
groups. 
 There are several limitations in this study. First, the CT-EIP only detects lab-confirmed 
cases. There are likely to be cases with mild disease who do not seek healthcare and some who 
do seek healthcare but do not get diagnostic testing specific to CDI. Therefore, these cases are 
never captured. Of cases detected in surveillance, only 51.4% of all cases had sufficient data to 
be included in analysis and there were significant differences between specific study 
characteristics in the non-study sample and study sample. The differences in epidemiologic 
classification, age, underlying medical conditions, and previous antibiotic use can be explained 
by a general understanding that those who are older, have previous antibiotic use, underlying 
                                                        
25 Cornely, Oliver A., Mark A. Miller, Thomas J. Louie, Derrick W. Crook, and Sherwood L. Gorbach. "Treatment of 
first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin." Clinical infectious diseases 55, 
no. suppl_2 (2012): S154-S161. 
26 Guery, Benoit, Francesco Menichetti, Veli-Jukka Anttila, Nicholas Adomakoh, Jose Maria Aguado, Karen 
Bisnauthsing, Areti Georgopali et al. "Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile 
infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial." The 
Lancet Infectious Diseases 18, no. 3 (2018): 296-307.Guery B et al. 2017 Lancet Infect Dis 296-307 
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medical conditions, and have a greater number of HCFO or CO-HCFA classifications are more 
likely to have a well-documented medical history and therefore complete data. Still, the 
differences in completeness of data by gender and race/ethnicity cannot be readily explained.  
Further, duration of treatment was defined by what the healthcare provider ordered per 
medical chart review by the CT-EIP data abstraction team. In clinical infectious disease, ordering 
providers typically prescribe antibiotics in intervals of seven or three days. Since numerous 
prescribed treatment periods fall outside of these intervals in this study, the prescribed treatment 
durations are particularly unusual, especially durations less than five days.  This can partly be 
explained by patients who received antibiotic treatment while hospitalized and after being 
discharged, as a patient could have received an antibiotic for the finite number of days 
hospitalized and an extended duration of treatment while discharged, leading to an 
unconventional treatment duration over the course of CDI. As for patients with a duration less 
than five days, rationales behind these short durations are unknown. Future CDI surveillance 
should consider collecting data on the rationale behind the prescribed treatment regimen, 
particularly for duration, from Connecticut providers. Aside from sporadic comments in the 
patient charts, rationales for concordant treatment deviation would better inform interventions to 
increase concordance. Study characteristics regarding the Connecticut provider such as their age 
and specialty could better inform strategies to increase concordance with the guidelines.  
 Lastly, treatment dosage, route of administration and frequency of dosing were not 
included in the definition of guideline concordance, and serum creatinine level was not included 
in the severity definition due to these variables being unavailable. Therefore, the definition of the 
treatment concordance variable in this study is not as specifically defined to match the true 
treatment guidelines.  
 19 
 This study focused on first-line treatment strategies, but fecal microbiota treatment 
(FMT) has emerged as a second-line/alternative treatment strategy for CDI leading to low 
recurrence rates CDI.27 For recurrent cases, the 2017 guidelines recommend adjusting the 
treatment regimen used from the initial episode as well as suggesting fecal microbiota transplant 
(FMT) for patients with multiple (≥3) recurrences. Concordance with these recommendations 
could be the subject of another study.  
 In conclusion, the updated 2017 IDSA/SHEA guidelines that focus on vancomycin as a 
first-line treatment in adult patients with CDI have led to a greater proportion of concordant care, 
with the highest frequency of CDI concordant care in 2019. Additional analysis of patients who 
are non-severe epidemiologic classified, the group with the highest rate of discordance, is needed 




















                                                        
27 Qureshi, Zaheer A., Sherry Reyes, Sharmi Biswas, Sri Lekha Bodepudi, Stacey E. Thomas, and Faryal Altaf. "Role of 
Fecal Microbiota Transplantation in Treating Inflammatory Bowel Disease and Clostridium difficile Infection: 











 (Incomplete Data) 




N = 1232 
P+ 
Case Classification 1137   0.882 
     Non-severe  21 (70.0) 811 (65.8)  
     Severe  8 (26.7) 381 (30.9)  
     Fulminant  1 (3.3) 40 (3.3)  
Year 552   0.220 
     2017  213 (34.6) 394 (32.0)  
     2018  239 (38.9) 465 (37.7)  
     2019  163 (26.5) 373 (30.3)  
Subsequent Recurrent CDI 553 51 (8.3)  136 (11.0)  0.06 
Female 552 403 (65.5) 725 (58.9) 0.006 
Age (Mean ± SD) 552 56.86 ± 22.16 65.61 ± 19.06 <0.001 
Age Group (six categories) 552   <0.001 
     <18  32 (5.2) 21 (1.7)  
     18-44  134 (21.8) 146 (11.9)  
     45-64  195 (31.7) 370 (30.0)  
     65-74  106 (17.2) 248 (20.1)  
     75-84  91 (14.8) 247 (20.1)  
     ≥85  57 (9.3) 200 (16.2)  
Race/Ethnicity~ 526   <0.001 
     NH White  402 (62.7) 890 (72.2)   
     NH Black  23 (3.6) 147 (11.9)  
     Hispanic   52 (8.1) 95 (7.7)  
     NH Other/Unk  164 (25.6) 100 (8.1)  
Epidemiologic Classification+ 552   <0.001 
     HCFO  18 (2.9) 171 (13.9)  
     CA  464 (75.5) 606 (49.2)  
     CO-HCFA  133 (21.6) 455 (36.9)  
Any Underlying Condition 552 253 (41.1) 235 (19.1) <0.001 
Previous Antibiotic Use 552 238 (38.7) 328 (26.6) <0.001 
~Race: Others/Unknown include those who identify as Pacific Islanders, those who identify as American 
Indian/Alaska Native, those who identify as Asian, and Unknown  
~ Non-Hispanic (NH) 










Table 2.  Description of the Study Population by Year, includes 2013-2016 data from Martinez et al. (2018)  
Characteristic 2013-2016 N=1513 (%)* 
2017 





Guideline Concordant Care 131 (8.7) 39 (10.0) 105 (23.0) 136 (36.9) 
Recurrent CDI 240 (15.9)  43 (11.0) 53 (11.6) 40 (10.8)  
Female 935 (61.8) 242 (61.9) 263 (57.7) 211 (57.2) 
Age (Mean ± SD) 64 ± 19#  65.89 ± 19.14 65.74 ± 19.10 64.66 ± 19.06 
Age Group     
     <20 38 (2.5) 9 (2.3) 8 (1.8) 8 (2.2) 
     20-44 205 (13.5) 41 (10.5) 56 (12.3) 45 (12.2) 
     45-64 456 (30.1) 116 (29.7) 140 (30.7) 112 (30.4) 
     65-74 307 (20.3) 79 (20.2) 90 (19.7) 73 (19.8) 
     75-84 283 (18.7) 79 (20.2) 83 (18.2) 82 (22.2) 
     ≥85 224 (14.8) 67 (17.1) 79 (17.3) 49 (13.3) 
Ethnicity     
     Hispanic 60 (4.0)  32 (8.2) 33 (7.2) 30 (8.1) 
     Non-Hispanic 1359 (89.8) 342 (87.5) 366 (80.3) 331 (89.7) 
     Other/Unknown 94 (6.2) 17 (4.4) 57 (12.5) 8 (2.2) 
Race     
     White 1166 (77.1) 296 (75.7) 316 (69.3) 282 (76.4) 
     Black 175 (11.6)  42 (10.7) 49 (10.8) 59 (16.0) 
     Other/Unknown 172 (11.4) 53 (13.6) 91 (20.0) 28 (7.6) 
Case Classification     
     Non-severe 1074 (71.0) 262 (67.0) 289 (63.4) 256 (69.4) 
     Severe 415 (27.4) 114 (29.2) 153 (33.6) 102 (27.6) 
     Fulminant 24 (1.6) 15 (3.8) 14 (3.1) 11 (3.0) 
First-line Treatment      
     Vancomycin 406 (26.8) 145 (37.1) 279 (61.2) 292 (79.1) 
     Metronidazole 902 (59.6) 223 (57.0) 174 (38.2) 72 (19.5) 
     Fidaxomicin 0 (0.0) 7 (1.8) 3 (0.7) 5 (1.4) 
     Rifampin 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 
     Nitazoxanide  0 (0.0) 3 (0.8) 0 (0.0) 0 (0.0) 
     Combination/Unknown+ 205 (13.6) 12 (3.1) 0 (0.0) 0 (0.0) 
Epidemiologic Classification     
     HCFO$ .. 54 (13.8) 74 (16.2) 35 (9.5) 
     CA$ .. 197 (50.4) 222 (48.7) 185 (50.1) 
     CO-HCFA$ .. 140 (35.8) 160 (35.1) 149 (40.4) 
Any Underlying Condition$ .. 89 (22.8) 93 (20.4) 53 (14.4) 
Previous Antibiotic Use$ .. 98 (25.1) 105 (23.0) 125 (33.9) 
# Mean and standard deviation presented as whole numbers per Martinez et al. (2018) 
+ Other/Unknown values: 2013-2016 values may have complete treatment data but Martinez et al. (2018) did not 
explicitly report the treatment regimen for these cases. 2017 cases had equal duration of treatment for two or more 
medications therefore leading to Other/Unknown classification.  
* % may not sum to 100 % due to rounding. 





Table 3.  Duration of antibiotic treatment (days) by study variables and specific antibiotics.  
Characteristic       Duration
+         
Unk  ≤5 6 7 8 9 10 11 12 13 14 ≥15 Total Mean ± SD 
Year               
     2017 3 96 5 9 13 23 80 12 8 24 74 47 394 10.12 ± 6.82 
     2018 0 112 10 13 2 36 118 14 7 20 67 66 465 10.92 ± 8.95 
     2019 0 62 2 4 6 26 149 12 9 16 45 42 373 10.87 ± 7.55 
Age Group                
     <18 0 2 0 0 0 3 11 2 0 1 1 1 21 11.00 ± 7.15 
     18-44 0 26 1 4 4 12 47 3 2 8 21 18 146 10.23 ± 5.52 
     45-64 0 74 2 8 7 21 109 12 7 26 60 44 370 10.99 ± 8.11 
     65-74 0 63 5 8 3 11 62 6 6 6 47 31 248 10.65 ± 8.32 
     75-84 2 56 7 3 4 20 61 8 7 11 34 34 247 10.73 ± 8.62 
     ≥85 1 49 2 3 3 18 57 7 2 8 23 27 200 10.19 ± 7.66 
Treatment                
     Vancomycin 0 99 6 9 10 54 240 26 19 37 118 114 732 12.20 ± 8.63 
     Metronidazole 3 162 11 16 11 28 96 11 5 22 67 37 469 8.33 ± 5.99 
     Fidaxomicin 0 0 0 0 0 2 10 0 0 1 0 2 15 11.87 ± 5.40 
     Rifampin 0 0 0 0 0 0 0 0 0 0 0 1 1 15.00 
     Nitazoxanide 0 0 0 1 0 0 0 1 0 0 0 1 3 12.33 ± 6.11 
     Other 0 9 0 0 0 1 1 0 0 0 1 0 12 4.25 ± 4.39 
Recurrent CDI               
    Yes 0 26 2 2 1 11 48 5 0 6 19 16 136 10.54 ± 6.97 
    No 3 244 15 24 20 74 299 33 24 54 167 139 1096 10.67 ± 8.01 
Case Classification               
     Non-severe 2 143 10 13 10 63 266 25 18 42 126 93 811 11.07 ± 8.02 
     Severe 1 114 5 8 10 20 77 11 5 18 58 54 381 9.92 ± 7.64 
     Fulminant 0 13 2 5 1 2 4 2 1 0 2 8 40 9.23 ± 7.37 
Epi Classification+                
     HCFO 1 42 2 5 4 15 30 5 4 9 27 27 171 11.06 ± 9.20 
     CA 1 121 8 11 11 38 200 14 12 33 91 66 606 10.50 ± 7.14 
     CO-HCFA 1 107 7 10 6 32 117 19 8 18 68 62 455 10.70 ± 8.34 
Gender               
     Female 2 163 9 14 12 52 211 20 11 34 120 77 725 10.51 ± 7.86 
     Male 1 107 8 12 9 33 136 18 13 26 66 78 507 10.85 ± 7.96 
Race/Ethnicity~               
     NH White 3 187 10 20 12 60 268 24 17 37 135 117 890 10.82 ± 7.99 
     NH Black 0 30 6 3 5 10 33 6 4 11 20 19 147 10.94 ± 8.69 
     Hispanic  0 22 0 2 3 6 20 5 2 7 18 10 95 9.93 ± 6.01 
     NH Other/Unk 0 31 1 1 1 9 26 3 1 5 13 9 100 9.48 ± 7.40 
Underlying Condition               
    Yes 0 46 0 5 5 21 75 7 2 12 39 23 235 10.47 ± 6.94 
    No 3 224 17 21 16 64 272 31 22 48 147 132 997 10.70 ± 8.11 
Prev Antibiotic Use               
    Yes 1 60 5 6 5 16 102 7 8 18 54 46 328 11.24 ± 7.93 
    No 2 210 12 20 16 69 245 31 16 42 132 109 904 10.44 ± 7.88 
Died in Treatment 0 41 0 2 2 2 4 0 0 0 1 5 57 5.11 ± 5.11 
 23 
+Unknown duration: Although duration is missing, enough data exists from first-line treatment to designate these as 




































































Table 4.  Description of Adult Cases by Severity (Initial Episode), 2017-2019 
 






Guideline Concordant Care 180 (22.8) 65 (17.7) 23 (62.2) <0.001 
Recurrent CDI 101 (12.8) 32 (8.7) 2 (5.4) 0.064 
Female 476 (60.3) 210 (57.1) 18 (48.7) 0.257 
Year    0.391 
     2017 256 (32.4) 114 (31.0) 14 (37.8)  
     2018 283 (35.8) 152 (41.3) 13 (35.1)  
     2019 251 (31.8) 102 (27.7) 10 (27.0)  
Age (Mean ± SD) 65.18 ± 17.83 68.43 ± 17.82 72.57 ± 15.33 0.002 
Age Group (five categories)    <0.001 
     18-44 100 (12.7) 43 (11.7) 3 (8.1)  
     45-64 277 (35.1) 87 (23.6) 4 (10.8)  
     65-74 142 (18.0) 87 (23.6) 13 (35.1)  
     75-84 158 (20.0) 78 (21.2) 8 (21.6)  
     ≥85 113 (14.3) 73 (19.8) 9 (24.3)  
Race/Ethnicity~    0.205 
     NH White 563 (71.3) 276 (75.0) 27 (73.0)  
     NH Black 106 (13.4) 32 (8.7) 4 (10.8)  
     Hispanic  65 (8.2) 24 (6.5) 3 (8.1)  
     NH Other/Unk 56 (7.1) 36 (9.8) 3 (8.1)  
Epidemiologic Classification+     <0.001 
     HCFO 81 (10.3) 73 (19.8) 8 (21.6)  
     CA 425 (53.8) 150 (40.8) 15 (40.5)  
     CO-HCFA 284 (36.0) 145 (39.4) 14 (37.8)  
Any Underlying Condition 154 (19.5) 65 (17.7) 4 (10.8) 0.349 
Any Previous Antibiotic Use 250 (31.7) 63 (17.1)  9 (24.3) <0.001 
     
*Percentages may not sum to 100% due to rounding. 
~Race/Ethnicity: Because the majority of those who identified as Hispanic did not identify in a race classification 
and a small portion of those identifying as Hispanic identified with a race classification, this variable encompasses 
all those who identified as Hispanic without regard to race classification.  
















Table 5.  Unadjusted associations between study variables and 2017 IDSA/SHEA Concordant Treatment Care in 
Adults, 2017-2019 
Characteristic N* 
N (%) With 
Concordant 
Care 
OR+ (95% CI) 
Recurrent CDI 135 100 (74.1) 1.24 (0.82, 1.88) 
Year    
     2017 384 34 (12.7) 1.00 
     2018 448 101 (37.7) 3.00 (1.98, 4.54) 
     2019 363 133 (49.6) 5.95 (3.94, 8.99) 
Female 704 153 (21.7) 0.91 (0.69, 1.20) 
Age (Mean ± SD) .. 67.04 ± 17.64  
Age Group (five categories)    
     18-44  146 32 (21.9) 1.00 
     45-64 368 78 (21.2) 0.96 (0.60, 1.53) 
     65-74 242 58 (24.0) 1.12 (0.69, 1.83) 
     75-84 244 51 (20.9) 0.94 (0.57, 1.55) 
     ≥85 195 49 (25.1) 1.20 (0.72, 1.99) 
Race/Ethnicity~    
     NH White 866 211 (24.4) 1.00 
     NH Black 142 29 (20.4) 0.80 (0.52, 1.23) 
     Hispanic  92 12 (13.0) 0.47 (0.25, 0.87) 
     NH Other/Unk 95 16 (16.8) 0.63 (0.36, 1.10) 
Case Classification    
     Non-severe 790 180 (22.8) 1.00 
     Severe 368 65 (17.7) 0.73 (0.53, 1.00) 
     Fulminant 37 23 (62.2) 5.57 (2.81, 11.04) 
Epidemiologic Classification     
     HCFO 162 30 (18.5) 1.00 
     CA 590 136 (23.1) 1.32 (0.85, 2.05) 
     CO-HCFA 443 102 (23.0) 1.32 (0.84, 2.07) 
Any Underlying Condition 223 46 (20.6) 0.88 (0.61, 1.26) 
Any Previous Antibiotic Use 322 72 (22.4) 1.00 (0.73, 1.35) 
* Numbers may not sum to total due to missing data 
















Table 6.  Unadjusted Associations between study variables and CDI Recurrence (≥ 18 Years Old), 2017-2019 
Characteristic N* N (%) With CDI Recurrence OR (95% CI) 
Guideline Concordant Care     
    Yes 268 35 (13.1) 1.00 
    No 927 100 (10.8) 0.81 (0.53, 1.22) 
Female 704 82 (11.7) 1.09 (0.76, 1.57) 
Year     
     2017 384 43 (11.2) 1.00  
     2018 448 52 (11.6) 1.04 (0.68, 1.60)  
     2019 363 40 (11.0) 0.98 (0.62, 1.55)  
Age (Mean ± SD) .. 70.06 ± 16.48 .. 
Age Group (five categories)    
     18-44 146 9 (6.2) 1.00 
     45-64 368 36 (9.8) 1.65 (0.77, 3.52) 
     65-74 242 30 (12.4) 2.15 (0.99, 4.68) 
     75-84 244 33 (13.5) 2.38 (1.11, 5.13) 
     ≥85 195 27 (13.9) 2.45 (1.11, 5.38) 
Race/Ethnicity~     
     NH White 866 108 (12.5) 1.00  
     NH Black 142 12 (8.5) 0.65 (0.35, 1.21)  
     Hispanic  92 9 (9.8) 0.76 (0.37, 1.56)  
     NH Other/Unk 95 6 (6.3) 0.47 (0.20, 1.11)  
Case Classification    
     Non-severe 790 101 (12.8) 1.00 
     Severe 368 32 (8.7) 0.65 (0.43, 0.99) 
     Fulminant 37 2 (5.4) 0.39 (0.09, 1.65) 
Epidemiologic Classification    
     HCFO 162 16 (9.9) 1.00 
     CA 590 62 (10.5) 1.07 (0.60, 1.91) 
     CO-HCFA 443 57 (12.9) 1.35 (0.75, 2.42) 
Any Underlying Condition 223 24 (10.8) 0.94 (0.59, 1.49) 
Any Previous Antibiotic Use 322 28 (8.7) 0.68 (0.44, 1.06) 
    
* Percentages may not sum to 100% due to rounding. 
 





Discordant Care 0.80 (0.53, 1.21) 0.288 
Age (Mean ± SD) 1.02 (1.01, 1.03) 0.006 
Case Classification   
     Non-severe 1.00 .. 
     Severe 0.63 (0.41, 0.95) 0.029 
     Fulminant 0.32 (0.08, 1.37) 0.126 
* Numbers may not sum to total due to missing data 
† P-value for analysis of variance Likelihood-Ratio X2 
 28 
^ Adjusting for sex, year, age, race/ethnicity, case classification, epidemiologic classification, any underlying 




Table 8. Secondary Treatment Permutations for Unadjusted Associations between Study Variables and CDI 
Recurrence (≥ 18 Years Old), 2017-2019 
Characteristic N* N (%) With CDI Recurrence OR (95% CI) 
Guideline Concordant Care     
    Yes 268 35 (13.1) 1.00 
    No 927 100 (10.8) 0.81 (0.53, 1.22) 
Concordant Antibiotic     
    Yes 707 83 (11.7) 1.00 
    No (metronidazole) 457 50 (10.9) 0.92 (0.64, 1.34) 
Those on Concordant Antibiotic    
    Duration 10 days 236 33 (14.0) 1.00 
    Duration <10 days 160 21 (13.1) 0.93 (0.52, 1.67) 
    Duration >10 days 311 29 (9.3) 0.63 (0.37, 1.08) 
Those on Metronidazole    
    Duration 10 days 89 14 (15.7) 1.00 
    Duration <10 days 228 20 (8.8) 0.52 (0.25, 1.07) 
    Duration >10 days 140 16 (11.4) 0.69 (0.32, 1.50) 
Those on Concordant Antibiotic    
    Duration 10 days 236 33 (14.0) 1.00 
    Duration ≤5 days 83 11 (13.3) 0.94 (0.45, 1.96) 
    Duration 6-9 days 77 10 (13.0) 0.92 (0.43, 1.96) 
    Duration 11-14 days 198 19 (9.6) 0.65 (0.36, 1.19) 
    Duration  ≥15 days 113 10 (8.9) 0.60 (0.28, 1.26) 
Those on Metronidazole    
    Duration 10 days 89 14 (15.7) 1.00 
    Duration ≤5 days 163 15 (9.2) 0.54 (0.25, 1.18) 
    Duration 6-9 days 65 65(7.7) 0.45 (0.15, 1.31) 
    Duration 11-14 days 103 10 (9.7) 0.58 (0.24, 1.37) 
    Duration  ≥15 days 37 6 (16.2) 1.04 (0.37, 2.95) 
 
 
